// App-Quantinova.ai

1088 : Phase (Ph) 1 study of oral seviteronel (VT-464), a dual CYP17-Lyase (L) inhibitor and androgen receptor (AR) antagonist, in patients (pts) with advanced AR+ triple negative (TNBC) or estrogen receptor (ER)+ breast cancer (BC).

Researchers

Presenter

  • Aditya Bardia

Principal Investigators

  • Noshir Anthony Dacosta

  • Nashat Y. Gabrail

  • Stephen Lemon

  • Michael A. Danso

  • Haythem Y. Ali

  • Ronald Alan Fleming

  • Michael R Kurman

  • Joel Robert Eisner

  • William Richard Moore

  • Ayca Gucalp

  • Tiffany A. Traina

Medical Centers

  • Massachusetts General Hospital Cancer Center, Boston, MA

  • North Shore Hematology Oncology Associates, East Setauket, NY

  • Gabrail Cancer Center, Canton, OH

  • Oncology Associates PC, Omaha, NE

  • Virginia Oncology Associates, Norfolk, VA

  • Henry Ford Health System, Detroit, MI

  • GlaxoSmithKline Rsrch and Dev, Research Triangle Park, NC

  • Innocrin Pharmaceuticals, Inc., Durham, NC

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • United States

Companies

  • Innocrin Pharmaceuti

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Triple-negative breast cancer

Biomarkers

  • Circulating tumor cells

  • Circulating DNA

Drug/Treatment

  • Seviteronel

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • I

Study Id's

  • NCT02580448

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved